BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 20298596)

  • 1. Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older.
    Vila-Corcoles A; Ochoa-Gondar O; Guzmán JA; Rodriguez-Blanco T; Salsench E; Fuentes CM;
    BMC Infect Dis; 2010 Mar; 10():73. PubMed ID: 20298596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study.
    Vila-Corcoles A; Salsench E; Rodriguez-Blanco T; Ochoa-Gondar O; de Diego C; Valdivieso A; Hospital I; Gomez-Bertomeu F; Raga X
    Vaccine; 2009 Mar; 27(10):1504-10. PubMed ID: 19171174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control study.
    Dominguez A; Salleras L; Fedson DS; Izquierdo C; Ruiz L; Ciruela P; Fenoll A; Casal J
    Clin Infect Dis; 2005 May; 40(9):1250-7. PubMed ID: 15825026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in patients with chronic pulmonary diseases: a matched case-control study.
    Vila-Corcoles A; Ochoa-Gondar O; Rodriguez-Blanco T; Gutierrez-Perez A; Vila-Rovira A;
    Hum Vaccin Immunother; 2012 May; 8(5):639-44. PubMed ID: 22634442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old--Taiwan's PPV vaccination program.
    Tsai YH; Hsieh MJ; Chang CJ; Wen YW; Hu HC; Chao YN; Huang YC; Yang CT; Huang CC
    Vaccine; 2015 Jun; 33(25):2897-902. PubMed ID: 25936662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period.
    De Serres G; Pilishvili T; Link-Gelles R; Reingold A; Gershman K; Petit S; Farley MM; Harrison LH; Lynfield R; Bennett NM; Baumbach J; Thomas A; Schaffner W; Beall B; Whitney C; Moore M
    Vaccine; 2012 Jun; 30(27):4067-72. PubMed ID: 22525797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical effectiveness of pneumococcal polysaccharide vaccine in men: California Men's Health Study.
    Hechter RC; Chao C; Jacobsen SJ; Slezak JM; Quinn VP; Van Den Eeden SK; Tseng HF
    Vaccine; 2012 Aug; 30(38):5625-30. PubMed ID: 22789510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales.
    Andrews NJ; Waight PA; George RC; Slack MP; Miller E
    Vaccine; 2012 Nov; 30(48):6802-8. PubMed ID: 23000122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasive pneumococcal disease among White Mountain Apache adults, 1991-2005.
    Bliss SJ; Larzalere-Hinton F; Lacapa R; Eagle KR; Frizzell F; Parkinson A; Reid R; Craig M; Santosham M; O'Brien KL
    Arch Intern Med; 2008 Apr; 168(7):749-55. PubMed ID: 18413558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recommendations for prevention of community-acquired pneumonia with bacteremia as the leading form of invasive pneumococcal infections in the population of people over 50 years of age and risk groups above 19 years of age].
    Albrecht P; Antczak A; Hryniewicz W; Skoczyńska A; Radzikowski A; Kedziora-Kornatowska K; Bernatowska E; Stompór T; Grodzicki T; Gyrczuk E; Imiela J; Jedrzejczak W; Windak A
    Pol Merkur Lekarski; 2014 Feb; 36(212):79-87. PubMed ID: 24720101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study.
    Leventer-Roberts M; Feldman BS; Brufman I; Cohen-Stavi CJ; Hoshen M; Balicer RD
    Clin Infect Dis; 2015 May; 60(10):1472-80. PubMed ID: 25669354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7-59 months. A matched case-control study.
    Domínguez A; Ciruela P; García-García JJ; Moraga F; de Sevilla MF; Selva L; Coll F; Muñoz-Almagro C; Planes AM; Codina G; Jordán I; Esteva C; Hernández S; Soldevila N; Cardeñosa N; Batalla J; Salleras L
    Vaccine; 2011 Nov; 29(48):9020-5. PubMed ID: 21939724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.
    Vila-Córcoles A; Ochoa-Gondar O; Hospital I; Ansa X; Vilanova A; Rodríguez T; Llor C;
    Clin Infect Dis; 2006 Oct; 43(7):860-8. PubMed ID: 16941367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pneumococcal disease in South Australia: vaccine success but no time for complacency.
    Johnson DR; D'Onise K; Holland RA; Raupach JC; Koehler AP
    Vaccine; 2012 Mar; 30(12):2206-11. PubMed ID: 22273663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invasive pneumococcal disease, comorbidities, and polysaccharide vaccine use in children aged 5-15 years in England and Wales.
    Ladhani SN; Andrews NJ; Waight P; Borrow R; Slack MP; Miller E
    Clin Infect Dis; 2014 Feb; 58(4):517-25. PubMed ID: 24300040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study.
    Barricarte A; Castilla J; Gil-Setas A; Torroba L; Navarro-Alonso JA; Irisarri F; Arriazu M
    Clin Infect Dis; 2007 Jun; 44(11):1436-41. PubMed ID: 17479939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population.
    Castañeda-Orjuela C; Alvis-Guzmán N; Paternina AJ; De la Hoz-Restrepo F
    Vaccine; 2011 Oct; 29(44):7644-50. PubMed ID: 21854825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
    Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B
    Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
    Lacapa R; Bliss SJ; Larzelere-Hinton F; Eagle KJ; McGinty DJ; Parkinson AJ; Santosham M; Craig MJ; O'Brien KL
    Clin Infect Dis; 2008 Aug; 47(4):476-84. PubMed ID: 18627249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly.
    Domínguez A; Izquierdo C; Salleras L; Ruiz L; Sousa D; Bayas JM; Nebot M; Varona W; Celorrio JM; Carratalà J;
    Eur Respir J; 2010 Sep; 36(3):608-14. PubMed ID: 20075048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.